Skip to main content
OpenTrials
Completed

NCT Number: NCT01527669

The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects

The objective of the study is to evaluate the pharmacokinetics of lovastatin and lovastatin acid of four 600 mg LipoCol Forte capsules compared to that of one 20 mg lovastatin Tablet after single oral administration in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

National Taiwan University Hospital

Taipei, Taiwan

About this study

This study is two-ways crossover design. The subjects will receive a dose of four 600 mg LipoCol Forte Capsules or 20 mg Mevacor Tablet in fasted state in the morning. There is a minimum of a 6-days washout period before crossover of treatments.

Each subject will be admitted before administration of the investigational product in each period. Study responsible personnel will give the subjects a single tablet or four capsules in fasted state in the morning. The blood samples will be drawn prior to the dosing, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours after the dosing.

Observations will be conducted up to 12 hours after the dosing. If no particular health abnormalities are observed in each period, the subjects will be discharged on 12 hours after the dosing.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must be at the age of 20-40 years old and be able to sign informed consent prior to study.
  • Body weight must be above 45 kilograms (kg) and within -20 to +20% of ideal body weight.
  • No clinically significant abnormalities were judged by the principal investigator based on the medical history, physical examination, electrocardiogram, chest X-ray, and routine laboratory evaluations.

Exclusion criteria

  • Use of any prescription medication, over-the-counter medications or vitamins within 14 days prior to dosing.
  • Participation in any clinical investigation within 2 months prior to dosing or longer as required by local regulation.
  • Donation or loss of more than 500 milliliter (mL) blood within 3 months prior to dosing.
  • Presence of liver disease (Glutamic Oxaloacetic Transaminase (GOT), Glutamic Pyruvic Transaminase (GPT) or Total-bilirubin greater than 2-fold normal values) or renal disease (blood urea nitrogen (BUN) or creatinine greater than 1.5-fold normal values).
  • Creatine kinase (CK) value greater than 1.5-fold normal value.
  • A known hypersensitivity to statins or their analogs.
  • Permanent confinement to an institution.
  • Individuals are judged by the investigator or co-investigator to be undesirable as subjects for other reasons.

Treatment and study plan

LipoCol Forte capsules

Drug

The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.

Lovastatin Tablet

Drug

The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.

Primary outcomes

  1. Evaluation of the pharmacokinetic parameters of lovastatin and lovastatin acid in healthy subjects

    Time frame: 1 weeks

    Plasma concentrations of lovastatin and lovastatin acid were detected at following time: (Pre-dose (T0), and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours after oral administration red yeast rice capsule (LipoCol Forte)or lovastatin. All pharmacokinetic parameters were determined with lovastatin and lovastatin acid concentrations by non-compartment methods.

Secondary outcomes

  1. The incidence rate of adverse event

    Time frame: 1 weeks

    The incidence rate of adverse event

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Collaborators

  • National Science and Technology Council, Taiwan

Registry information

Official study title

The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects.

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Feb 7, 2012
Registry last updated
Jul 11, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.